Company Overview
Progyny, Inc. operates as a benefits management company within the United States, specializing in the provision of fertility, family building, and women's health benefits solutions. The company functions within the broader Healthcare sector and specifically the Healthcare Plans industry, positioning itself to serve employers seeking differentiated benefits plan designs that include smart cycle treatment bundles and personalized concierge-style support. In terms of scale, Progyny holds a market capitalization of $1.46B and generated annual revenue of $1.29B over the trailing twelve months, while employing a workforce of 835 individuals. These valuation and revenue figures indicate that the company maintains a significant presence in its niche, commanding a market capitalization that reflects substantial investor interest despite operating in a specialized segment of the healthcare landscape.
Financial Health
The company reported a trailing twelve-month revenue of $1.29B, with a corresponding net income of $58.52M and an EBITDA of $97.92M. The substantial gap between the $1.29B in revenue and the $58.52M in net income reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, consume approximately 95.5% of total revenue before accounting for interest and taxes. Progyny demonstrates robust financial flexibility with free cash flow of $212.50M, a figure that exceeds its net income and indicates strong operational efficiency in converting sales into cash reserves. The balance sheet shows a cash position of $310.10M against total debt of $27.73M, resulting in a debt-to-equity ratio of 5.37, which suggests a capital structure heavily reliant on equity rather than debt financing. Despite the high debt-to-equity ratio, the current ratio stands at 2.73, indicating that the company holds 2.73 times more current assets than current liabilities and thus possesses strong short-term liquidity to meet its immediate obligations. Return on Equity is calculated at 12.5% and Return on Assets is 8.6%, metrics that reveal management effectiveness in generating profits relative to shareholder equity and total assets, respectively.
Valuation Assessment
Valuation metrics for Progyny show a trailing P/E ratio of 27.41 compared to a forward P/E of 8.48, implying that the market currently prices in significantly higher future earnings growth relative to current profitability. The price-to-book ratio is 2.86, indicating that the market values the company at nearly three times its book value and suggesting a premium assigned to its intangible assets and growth prospects. Alternative valuation metrics include a price-to-sales ratio of 1.13 and an EV/EBITDA of 12.28, which suggest the company is valued at slightly more than one dollar of revenue and offers a multiple that reflects its earnings power relative to enterprise value. Regarding price volatility, the stock has a 52-week high of $28.75 and a 52-week low of $16.75, meaning the current trading price sits approximately 49.2% below the 52-week high and 39.6% above the 52-week low based on the provided range. The beta value is 1.01, which indicates that the stock's price volatility moves in tandem with the broader market, exhibiting neither significant defensive characteristics nor heightened aggressive fluctuation compared to the general market index.
Growth & Income
The company exhibits revenue growth of 6.7% year-over-year alongside earnings growth of 20.6% year-over-year, demonstrating that earnings are expanding at a pace more than three times faster than revenue, which often implies improving operational leverage or margin expansion. As a non-dividend payer, Progyny does not distribute a dividend yield or maintain a payout ratio, as the dividend yield is listed as N/A and the payout ratio is 0.0%. Consequently, the company retains all its net income, reinvesting these earnings directly into business growth initiatives, capital expansion, or share repurchases rather than distributing cash to shareholders. The overall growth and income profile is characterized by high earnings acceleration relative to top-line growth and a total retention of profits to fuel future expansion within the women's health sector.
Peer Comparison
Progyny, Inc. (PGNY) operates in the Healthcare Plans industry. Here is how it compares to its closest peers by market capitalization:
The Healthcare Plans industry average P/E ratio is 45.1x. Progyny, Inc. trades at a P/E of 32.3.